Cerebro-Protective effect of bosentan in brain ischemia reperfusion injury
الباحث الأول:
Ahmed M Almudhafar
الباحثين الآخرين:
Ahmed J. Hussien
1
,Zahraa K Alhassani
2
, Najah R Hadi
1
, Bassim I Mohammad
3
,
Dina A Jamil
4
, Hayder A Al-Aubaidy
المجلة:
Annals of Tropical Medicine & Public Health
تاريخ النشر:
None
مختصر البحث:
Background: Ischemia reperfusion injury following acute ischemic insult is responsible for extension of injury.
Bosentan is an endothelin receptor antagonist, which is currently used as a strong vasoconstrictor. This study aims to
investigate the …
Background: Ischemia reperfusion injury following acute ischemic insult is responsible for extension of injury.
Bosentan is an endothelin receptor antagonist, which is currently used as a strong vasoconstrictor. This study aims to
investigate the effects of bosentan on ischemia reperfusion injury after brain ischemic stroke in rat model.
Methods: Forty male Wistar rats were randomly allocated into four study groups: Sham group: Rats underwent the
anesthesia & surgery for an identical period to the other 3 study groups without intervention. Control group: Rats
underwent anesthesia & surgery including bilateral common carotid artery ligation (BCCAL) for 30 minutes and
then reperfusion for 1 hour. Vehicle group: Four days before ischemia, rats were administered with a vehicle (5%
gummi arabicum) and then anesthesia &BCCAL surgery were performed. Bosentan treat group: Four days beforeischemia, rats were administered with bosentan (100mg/ kg/day) and then anesthesia & BCCAL surgery were
performed.
Results: Bosentan treated group exhibited lower concentration of interleukin 6 (IL-6)in the brain (2168.0±30.67
pg/mL) than in the control group (2571.37±96.58 pg/mL) (P≤0.05). In addition, interleukin 10 (IL-10) levels were
significantly high in the bosentan group (275.7±15.97 pg/mL) when compared to the control group (244.05±12.23
pg/mL) (P≤0.05). This was associated with a non-significant reduction in the brain levels of endothelia nitric oxide
synthase (eNOS) in the bosentan treated groups (90.23±1.14 ng/mL) when compared to the control group
(90.94±2.48), (P>0.05).
Conclusion: Bosentan treatment have protective effects against the inflammatory damage following ischemia
reperfusion injury following acute myocardial infarction.
